Sector consensus Charles River Laboratories International, Inc.
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 226.58 USD | -1.18% |
|
+0.99% | +13.59% |
| 07-20 | Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… |  |
| 07-13 | BofA Adjusts Price Target on Charles River Laboratories International to $264 From $220 | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 230.93 | +1.92% | 15 | ||||||
| 677.61 | +23.65% | 23 | ||||||
| 207 | +9.39% | 21 | ||||||
| 415.64 | +27.54% | 27 | ||||||
| 232 | +11.51% | 19 | ||||||
| 256,664.68 | +44.52% | 24 | ||||||
| 570.67 | -5.11% | 12 | ||||||
| 267.71 | +19.91% | 18 | ||||||
| 72.1 | +8.58% | 14 | ||||||
| 181.81 | +9.68% | 16 | ||||||
| 70 | -2.23% | 12 | ||||||
| 138.56 | +22.84% | 6 | ||||||
| 130.53 | -2.79% | 12 | ||||||
| 37.73 | -2.07% | 11 | ||||||
| 91.65 | +62.07% | 20 | ||||||
| 127.05 | +14.9% | 21 | ||||||
| 610.05 | +87.54% | 19 | ||||||
| 53.59 | +1.32% | 17 | ||||||
| 133.31 | -2.06% | 13 | ||||||
| 44.07 | +6.52% | 14 | ||||||
| Average | 13,047.83 | +16.88% | 17 | ||||||
| Weighted average by Cap. | 20,632.57 | +18.11% | 19 |
Select your edition
All financial news and data tailored to specific country editions
